BRAF and melanoma: In patients with NSCLC, the prognostic impact of non-V600 mutations is not consistent across reports (22, 23), while in patients with melanoma, there was no significant survival difference between non-V600 mutations, V600 BRAF-mutation, and BRAF wild-type (24).